Is A Downturn Overdue? MetLife, Inc. (MET), Aclaris Therapeutics, Inc. (ACRS)?

The shares of MetLife, Inc. (NYSE:MET) has been pegged with a rating of In-line by Evercore ISI in its latest research note that was published on July 16th, 2019. Evercore ISI wasn’t the only research firm that published a report of MetLife, Inc., with other equities research analysts also giving their opinion on the stock. Sandler O’Neill advised investors in its research note published on March 19th, 2019, to Hold the MET stock. The stock had earned Buy rating from BofA/Merrill when it published its report on January 16th, 2019. The stock was given Buy rating by Sandler O’Neill in its report released on January 2nd, 2019. Goldman was of a view that MET is Neutral in its latest report on June 4th, 2018. Credit Suisse thinks that MET is worth Outperform rating. This was contained in the firm’s report on April 25th, 2018 in which the stock’s price target was also moved to $67.

Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 8 believe it has the potential for further growth, thus rating it as Hold while 5 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $53.53. The price of the stock the last time has raised by 24.23% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 38.35.

The shares of the company dipped by -0.55% during the trading session on Friday, reaching a low of $46.56 while ending the day at $46.91. During the trading session, a total of 5.32 million shares were traded which represents a -16.01% decline from the average session volume which is 4.59M shares. MET had ended its last session trading at 47.17. MetLife, Inc. currently has a market cap of $45.56B, while its P/E ratio stands at 7.71, while its P/E earnings growth sits at 0.69, with a beta of 1.09. MetLife, Inc. debt-to-equity ratio currently stands at 0.28, while its quick ratio hovers at . MET 52-week low price stands at $37.76 while its 52-week high price is $51.16.

The company in its last quarterly report recorded $1.38 earnings per share which is above the $1.34 predicted by most analysts. The MetLife, Inc. generated $16,454.00 million in revenue during the last quarter, which is slightly lower than the $16,549.30 million predicted by analysts. In the second quarter last year, the firm recorded $1.48 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -7.25%. MetLife, Inc. has the potential to record 6.08 EPS for the current fiscal year, according to equities analysts.

Investment analysts at SVB Leerink published a research note on June 27th, 2019 where it informed investors and clients that Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is now rated as Mkt Perform. Sandler O’Neill also rated ACRS as Downgrade on March 19th, 2019, with its price target of $116 suggesting that ACRS could surge by 93.57% from its current share price. Even though the stock has been trading at $0.99/share, analysts expect it to surge higher by -9.08% to reach $14.00/share. It started the day trading at $0.97 and traded between $0.891 and $0.90 throughout the trading session.

A look at its technical shows that ACRS’s 50-day SMA is 2.93 while its 200-day SMA stands at 6.18. At the moment, only of Aclaris Therapeutics, Inc. shares were sold short. The company’s average trading volume currently stands at 834.19K shares, which means that the short-interest ratio is just 2.51 days. Over the past seven days, the company moved, with its shift of -18.91%. Looking further, the stock has dropped -84.97% over the past 90 days while it lost -87.16% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Franklin Advisers Inc bought more ACRS shares, increasing its portfolio by +0.47% during the last quarter. This move now sees Franklin Advisers Inc purchasing 18,392 shares in the last quarter, thus it now holds 3,971,595 shares of ACRS, with a total valuation of $8,697,793. BlackRock Fund Advisors meanwhile sold more ACRS shares in the recently filed quarter, changing its stake to $6,365,653 worth of shares. Deerfield Management Company LP followed the path by decreasing its ACRS portfolio by -51.67% in the quarter. This means that Deerfield Management Company LP sold -3,045,042 shares in the last quarter and now controls 2,848,374 shares of the ACRS stock, with the valuation hitting $6,237,939.

Similarly, Rock Springs Capital Management L increased its Aclaris Therapeutics, Inc. shares by +23.53% during the recently filed quarter. After buying 400,000 shares in the last quarter, the firm now controls 2,100,000 shares of Aclaris Therapeutics, Inc. which are valued at $4,599,000. In the same vein, Broadfin Capital LLC increased its Aclaris Therapeutics, Inc. shares by during the most recent reported quarter. The firm bought 153,423 shares during the quarter which increased its stakes to 2,030,925 shares and is now valued at $4,447,726. Following these latest developments, around 0.40% of Aclaris Therapeutics, Inc. stocks are owned by institutional investors and hedge funds.